Influence of particle size on the in vitro and in vivo anti-inflammatory and anti-allergic activities of a curcumin lipid nanoemulsion

Onodera,Takefumi; Kuriyama,Isoko; Andoh,Tooru; Ichikawa,Hideki; Sakamoto,Yuka; Lee-Hiraiwa,Eibai; Mizushina,Yoshiyuki

doi:10.3892/ijmm.2015.2186

Influence of particle size on the in vitro and in vivo anti-inflammatory and anti-allergic activities of a curcumin lipid nanoemulsion

Authors:
- Takefumi Onodera
- Isoko Kuriyama
- Tooru Andoh
- Hideki Ichikawa
- Yuka Sakamoto
- Eibai Lee-Hiraiwa
- Yoshiyuki Mizushina
View Affiliations

Affiliations: Laboratory of Food and Nutritional Sciences, Faculty of Nutrition, Kobe Gakuin University, Kobe, Hyogo 651-2180, Japan, Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe, Hyogo 651-8586, Japan
Published online on: April 16, 2015 https://doi.org/10.3892/ijmm.2015.2186
Pages: 1720-1728

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The polyphenolic compound, curcumin, is a natural yellow pigment component of turmeric. It exerts various biological effects, such as anti-inflammatory effects, and we have previously demonstrated that curcumin is a specific inhibitor of DNA polymerase λ. Curcumin is characterized by poor bioavailability as it is water-insoluble, is poorly absorbed and is systemically eliminated. In order to increase the bioavailability of curcumin, in this study, we produced a curcumin-loaded lipid nanoemulsion of various particle sizes (50, 100 and 200 nm). The curcumin lipid nanoemulsion was prepared by a modified thin-film hydration method followed by sonication. To identify the optimal particle size which exhibits the strongest physiological activity, we investigated the inhibitory effects of the obtained nanoemulsions against inflammatory and allergic activities. In in vitro cell culture experiments, the 100-nm curcumin lipid nanoemulsion showed the most prominent inhibitory effect on the production of tumor necrosis factor-α (TNF-α) induced by lipopolysaccharide (LPS) in RAW264.7 murine macrophages, and on the release of β-hexosaminidase induced by the calcium ionophore, A23187, in rat basophilic leukemia RBL-2H3 cells. In an in vivo experiment, in which mice were administered the curcumin-loaded lipid nanoemulsion of various particle sizes, the 100-nm curcumin lipid nanoemulsion showed the most prominent anti-inflammatory and anti-allergic effects, inhibiting 12-O-tetradecanoylphorbol-13-acetate-induced inflammatory ear edema and immunoglobulin E (IgE)-induced passive cutaneous anaphylactic (PCA) reaction. The effects of particle size on serum curcumin absorption were also assessed in mice, and the 100-nm lipid nanoemulsion showed the greatest absorption. The results from our study suggest that the physiological activities of curcumin lipid nanoemulsions differ depending on particle size. Our data indicate that the curcumin lipid nanoemulsion with a particle size of 100 nm has potential for use in enhancing the bioavailability and medical value of curcumin.

View Figures

View References

1	Anand P, Kunnumakkara AB, Newman RA and Aggarwal BB: Bioavailability of curcumin: Problems and promises. Mol Pharm. 4:807–818. 2007. View Article : Google Scholar : PubMed/NCBI
2	Ammon HP, Safayhi H, Mack T and Sabieraj J: Mechanism of antiinflammatory actions of curcumine and boswellic acids. J Ethnopharmacol. 38:113–119. 1993. View Article : Google Scholar : PubMed/NCBI
3	Banerjee A and Nigam SS: Antimicrobial efficacy of the essential oil of Curcuma longa. Indian J Med Res. 68:864–866. 1978.PubMed/NCBI
4	Bhavani Shankar TN and Sreenivasa Murthy V: Effect of turmeric (Curcuma longa) fractions on the growth of some intestinal and pathogenic bacteria in vitro. Indian J Exp Biol. 17:1363–1366. 1979.PubMed/NCBI
5	Sawada T, Yamahara J, Shimazu S and Ohta T: Evaluation of crude drugs by bioassay. III. Comparison with local variation of contents and the fungistatic action of essential oil from the root of Curcuma longa. Shoyakugaku Zasshi. 25:11–16. 1971.
6	Rao DS, Sekhara NC, Satyanarayana MN and Srinivasan M: Effect of curcumin on serum and liver cholesterol levels in the rat. J Nutr. 100:1307–1315. 1970.PubMed/NCBI
7	Limtrakul P, Anuchapreeda S, Lipigorngoson S and Dunn FW: Inhibition of carcinogen induced c-Ha-ras and c-fos proto-oncogenes expression by dietary curcumin. BMC Cancer. 1:1–7. 2001. View Article : Google Scholar : PubMed/NCBI
8	Anuchapreeda S, Limtrakul P, Thanarattanakorn P, Sittipreechacharn S and Chanarat P: Inhibitory effect of curcumin on WT1 gene expression in patient leukemic cells. Arch Pharm Res. 29:80–87. 2006. View Article : Google Scholar : PubMed/NCBI
9	Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Chanarat P and Limtrakul P: Curcumin inhibits WT1 gene expression in human leukemic K562 cells. Acta Pharmacol Sin. 27:360–366. 2006. View Article : Google Scholar : PubMed/NCBI
10	Anuchapreeda S, Tima S, Duangrat C and Limtrakul P: Effect of pure curcumin, demethoxycurcumin, and bisdemethoxycurcumin on WT1 gene expression in leukemic cell lines. Cancer Chemother Pharmacol. 62:585–594. 2008. View Article : Google Scholar
11	Polasa K, Raghuram TC, Krishna TP and Krishnaswamy K: Effect of turmeric on urinary mutagens in smokers. Mutagenesis. 7:107–109. 1992. View Article : Google Scholar : PubMed/NCBI
12	Roy RG, Madesayaa NM, Ghosh RB, Gopalakrishnan DV, Murthy NN, Dorairaj TJ and Sitaraman NL: Study on inhalation therapy by an indigenous compound on P. vivax and P. falciparum infections - a preliminary communication. Indian J Med Res. 64:1451–1455. 1976.PubMed/NCBI
13	Azuine MA and Bhide SV: Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. Nutr Cancer. 17:77–83. 1992. View Article : Google Scholar : PubMed/NCBI
14	Dorai T, Cao YC, Dorai B, Buttyan R and Katz AE: Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate. 47:293–303. 2001. View Article : Google Scholar : PubMed/NCBI
15	Anuchapreeda S, Muangmoonchai R and Limtrakul P: Effect of curcuminoids on MDR1 gene promoter activity in human cervical carcinoma cells. Chiang Mai Med Bull. 41:189–202. 2002.
16	Mizushina Y, Hirota M, Murakami C, Ishidoh T, Kamisuki S, Shimazaki N, Takemura M, Perpelescu M, Suzuki M, Yoshida H, et al: Some anti-chronic inflammatory compounds are DNA polymerase λ-specific inhibitors. Biochem Pharmacol. 66:1935–1944. 2003. View Article : Google Scholar : PubMed/NCBI
17	Takeuchi T, Ishidoh T, Iijima H, Kuriyama I, Shimazaki N, Koiwai O, Kuramochi K, Kobayashi S, Sugawara F, Sakaguchi K, et al: Structural relationship of curcumin derivatives binding to the BRCT domain of human DNA polymerase λ. Genes Cells. 11:223–235. 2006. View Article : Google Scholar : PubMed/NCBI
18	Nishida M, Nishiumi S, Mizushina Y, Fujishima Y, Yamamoto K, Masuda A, Mizuno S, Fujita T, Morita Y, Kutsumi H, et al: Monoacetylcurcumin strongly regulates inflammatory responses through inhibition of NF-κB activation. Int J Mol Med. 25:761–767. 2010.PubMed/NCBI
19	Mizushina Y, Nishida M, Azuma T and Yoshida M: Inhibition of DNA polymerase λ, a DNA repair enzyme, and anti-inflammation: chemical knocked out analysis for DNA polymerase λ using curcumin derivatives. DNA Repair and Human Health. Chapter 31. InTech. Vengrova S: pp. 777–792. 2011
20	Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21:2895–2900. 2001.PubMed/NCBI
21	Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP and Gescher AJ: Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev. 14:120–125. 2005.PubMed/NCBI
22	Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, et al: A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 68:157–164. 2011. View Article : Google Scholar
23	Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, et al: Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res. 10:6847–6854. 2004. View Article : Google Scholar : PubMed/NCBI
24	Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z and Brenner DE: Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 17:1411–1417. 2008. View Article : Google Scholar : PubMed/NCBI
25	Porter CJ, Trevaskis NL and Charman WN: Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 6:231–248. 2007. View Article : Google Scholar : PubMed/NCBI
26	Solans C, Izquierdo P, Nolla J, Azemar N and Garcia-Celma MJ: Nanoemulsions. Curr Opin Colloid Interface Sci. 10:102–110. 2005. View Article : Google Scholar
27	Wheeler JJ, Wong KF, Ansell SM, Masin D and Bally MB: Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. J Pharm Sci. 83:1558–1564. 1994. View Article : Google Scholar : PubMed/NCBI
28	Liu F and Liu D: Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm Res. 12:1060–1064. 1995. View Article : Google Scholar : PubMed/NCBI
29	Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, Sasagawa K, Kobayashi T and Hisaoka M: Lipid emulsions of palmitoylrhizoxin: Effects of composition on lipolysis and biodistribution. Biopharm Drug Dispos. 17:331–342. 1996. View Article : Google Scholar : PubMed/NCBI
30	Wang Y, Mesfin GM, Rodríguez CA, Slatter JG, Schuette MR, Cory AL and Higgins MJ: Venous irritation, pharmacokinetics, and tissue distribution of tirilazad in rats following intravenous administration of a novel supersaturated submicron lipid emulsion. Pharm Res. 16:930–938. 1999. View Article : Google Scholar : PubMed/NCBI
31	Maranhão RC, Garicochea B, Silva EL, Dorlhiac-Llacer P, Cadena SM, Coelho IJ, Meneghetti JC, Pileggi FJ and Chamone DA: Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res. 54:4660–4666. 1994.PubMed/NCBI
32	Miyamoto M, Hirano K, Ichikawa H, Fukumori Y, Akine Y and Tokuuye K: Preparation of gadolinium-containing emulsions stabilized with phosphatidylcholine-surfactant mixtures for neutron-capture therapy. Chem Pharm Bull (Tokyo). 47:203–208. 1999. View Article : Google Scholar
33	Miyamoto M, Hirano K, Ichikawa H, Fukumori Y, Akine Y and Tokuuye K: Biodistribution of gadolinium incorporated in lipid emulsions intraperitoneally administered for neutron-capture therapy with tumor-bearing hamsters. Biol Pharm Bull. 22:1331–1340. 1999. View Article : Google Scholar
34	Razin E, Mencia-Huerta JM, Stevens RL, Lewis RA, Liu FT, Corey E and Austen KF: IgE-mediated release of leukotriene C4, chondroitin sulfate E proteoglycan, β-hexosaminidase, and histamine from cultured bone marrow-derived mouse mast cells. J Exp Med. 157:189–201. 1983. View Article : Google Scholar : PubMed/NCBI
35	Sato H, Kobayashi Y, Hattori A, Suzuki T, Shigekawa M and Jippo T: Inhibitory effects of water-soluble low-molecular-weight β-(1,3–1,6) D-glucan isolated from Aureobasidium pullulans 1A1 strain black yeast on mast cell degranulation and passive cutaneous anaphylaxis. Biosci Biotechnol Biochem. 76:84–88. 2012. View Article : Google Scholar
36	Soler-Rodriguez AM, Zhang H, Lichenstein HS, Qureshi N, Niesel DW, Crowe SE, Peterson JW and Klimpel GR: Neutrophil activation by bacterial lipoprotein versus lipopolysaccharide: differential requirements for serum and CD14. J Immunol. 164:2674–2683. 2000. View Article : Google Scholar : PubMed/NCBI
37	Suzuki T, Hashimoto S, Toyoda N, Nagai S, Yamazaki N, Dong HY, Sakai J, Yamashita T, Nukiwa T and Matsushima K: Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood. 96:2584–2591. 2000.PubMed/NCBI
38	Aggarwal BB: Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol. 3:745–756. 2003. View Article : Google Scholar : PubMed/NCBI
39	Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Chisei R and Ogawa H: Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest. 109:1351–1359. 2002. View Article : Google Scholar : PubMed/NCBI
40	Metcalfe DD, Peavy RD and Gilfillan AM: Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol. 124:639–646. 2009. View Article : Google Scholar : PubMed/NCBI
41	Payton F, Sandusky P and Alworth WL: NMR study of the solution structure of curcumin. J Nat Prod. 70:143–146. 2007. View Article : Google Scholar : PubMed/NCBI
42	Li L, Braiteh FS and Kurzrock R: Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 104:1322–1331. 2005. View Article : Google Scholar : PubMed/NCBI
43	Maiti K, Mukherjee K, Gantait A, Saha BP and Mukherjee PK: Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 330:155–163. 2007. View Article : Google Scholar
44	Mizushina Y, Maeda N, Kawasaki M, Ichikawa H, Murakami C, Takemura M, Xu X, Sugawara F, Fukumori Y, Yoshida H, et al: Inhibitory action of emulsified sulfoquinovosyl acylglycerol on mammalian DNA polymerases. Lipids. 38:1065–1074. 2003. View Article : Google Scholar : PubMed/NCBI
45	Anuchapreeda S, Fukumori Y, Okonogi S and Ichikawa H: Preparation of lipid nanoemulsions incorporating curcumin for cancer therapy. J Nanotechnol Article. 2012:2703832012.
46	Hung CF, Hwang TL, Chang CC and Fang JY: Physicochemical characterization and gene transfection efficiency of lipid emulsions with various co-emulsifiers. Int J Pharm. 289:197–208. 2005. View Article : Google Scholar : PubMed/NCBI
47	Chinsriwongkul A, Opanasopit P, Ngawhirunpat T, Chareansriwilaiwat N, Sila-On W and Ruktanonchai U: Physicochemical properties of lipid emulsions formulated with high-load all-trans-retinoic acid. PDA J Pharm Sci Technol. 61:461–471. 2007.
48	Texier I, Goutayer M, Da Silva A, Guyon L and Djaker N: Cyanine-loaded lipid nanoparticles for improved in vivo fluorescence imaging. J Biomed Opt. 14:0540052009. View Article : Google Scholar : PubMed/NCBI
49	Goutayer M, Dufort S, Josserand V, Royere A, Heinrich E, Vinet F, Bibette J, Coll JL and Texier I: Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging. Eur J Pharm Biopharm. 75:137–147. 2010. View Article : Google Scholar : PubMed/NCBI
50	Hurstand WJ and Martin RA Jr: The analysis of phospholipids in soy lecithin by HPLC. J Am Oil Chem Soc. 61:1462–1463. 1984. View Article : Google Scholar
51	Sonneville-Aubrun O, Simonnet JT and L’Alloret F: Nanoemulsions: A new vehicle for skincare products. Adv Colloid Interface Sci. 108–109:145–149. 2004. View Article : Google Scholar
52	Patel D and Sawant KK: Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS). Drug Dev Ind Pharm. 33:1318–1326. 2007. View Article : Google Scholar : PubMed/NCBI